Sodium, Valporate With Valporic acid
Controlled-release tablets of sodium valproate and valproic acid are a pharmaceutical formulation designed to deliver a consistent and sustained release of these active ingredients over an extended period. Sodium valproate and valproic acid are both anticonvulsant medications commonly used in the treatment of epilepsy, bipolar disorder, and other neurological conditions.
The tablets contain 300 mg of sodium valproate and valproic acid, providing an optimal therapeutic dose. The controlled release technology allows for the gradual and controlled release of the medication into the body, ensuring a steady blood concentration throughout the day.
The formulation of these tablets involves incorporating the active ingredients into a special matrix or coating that regulates their release. This matrix or coating is designed to dissolve gradually, allowing for the slow release of sodium valproate and valproic acid into the gastrointestinal tract.
It is important to note that sodium valproate and valproic acid have different pharmacokinetic profiles. Sodium valproate is rapidly converted to valproic acid in the body, which is responsible for its therapeutic effects. Both compounds act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain, which helps to control seizures and stabilize mood.
Here’s a general guideline on how to use controlled-release tablets of sodium valproate and valproic acid:
Controlled-release tablets of sodium valproate and valproic acid offer several benefits compared to immediate-release formulations. Here are some potential advantages:
Sustained therapeutic effect: Controlled-release tablets gradually release the medication into the body over an extended period, maintaining a consistent blood concentration of the active ingredients.
Improved patient compliance: With controlled-release tablets, patients typically require fewer doses per day compared to immediate-release formulations. This simplifies the dosing regimen and may enhance patient adherence to the prescribed treatment plan.
Smoother side effect profile: The controlled release of sodium valproate and valproic acid can potentially result in a smoother and more predictable plasma concentration profile. This may help decrease the occurrence of certain side effects associated with rapid increases or decreases in drug levels
Reduced peak and trough variability: Controlled-release tablets provide a more consistent drug release, reducing these fluctuating drug levels and achieving a more stable therapeutic range.
Enhanced convenience: The prolonged duration of action offered by controlled-release tablets means that patients do not have to take medication as frequently throughout the day.
Potential for improved efficacy: By maintaining a steady concentration of the active ingredients in the bloodstream, controlled-release tablets may optimize the effectiveness of sodium valproate and valproic acid therapy.
Here are the side effects of controlled-release tablets of Sodium Valproate and Valproic Acid (300 mg):
Precautions for controlled-release tablets of Sodium Valproate and Valproic Acid (300 mg):